# Arsenal Biosciences, Inc.: Phase 1 study terminated, 19 enrolled (Carcinoma, Ovarian Epithelial, Ovarian Neoplasms)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Arsenal Biosciences, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer |
| NCT ID | NCT05617755 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Diseases |
| Intervention types | biological |
| Target enrollment | 19 |
| Site countries | United States |
| Posted | 2022-11-15 |
| Planned start | 2022-11-29 |
| Event | Terminated |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05617755). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.